Figure 3
(A) Four-gene classification model for prediction of cetuximab benefit measured by disease control rate in KRAS wt patients. (B) Four-gene classification model for prediction of cetuximab benefit measured by objective response rate in KRAS wt patients. (C) Performance measures of two patient classifiers (disease control endpoint). (D) Performance measures of two patient classifiers (objective response endpoint). The four-gene classifier includes DUSP6, SLC23A2 and the average of EREG and AREG. EREG and AREG were averaged because they tightly co-express in these colon cancer specimens (R2=0.83).
